Pharmaceutical company Teva USA today announced that it will resume production of childhood cancer drug vincristine after a recent shortage which led to patients missing doses of the vital chemotherapy.

“I’m pleasantly surprised to see the announcement and it’s the right decision,” said Dr. Yoram Unguru, a pediatric oncologist at the Herman and Walter Samuelson Children’s Hospital at Sinai in Baltimore and faculty member at the Johns Hopkins Berman Institute of Bioethics.  “Patients are going to benefit, but it wont help immediately,” he added.

The company came under intense pressure for the decision to cease production in March 2019 after claiming its product only made up 3% of the market share, with Pfizer producing the remainder. One White House petition asking the government to intervene in the shortage has over 100,000 signatures and another requesting Teva resume production has over 200,000 supporters.

However, the decision to make the drug again will not make any short-term impact on the ongoing shortage with the announcement from Teva stating that production will resume “as early in 2020 as possible,” without specifying a date.

“One of the hardest things in being able to cope with and address shortages, is how long is the shortage is going to last, is it 2 weeks or two months? Knowing this allows you to plan for your expected patients, in those respects I’d like a bit more information from Teva,” said Unguru. Reasd more at Forbes